Literature DB >> 965497

The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man.

C J Jaffe, J P Atkinson, M M Frank.   

Abstract

To define the pathophysiologic mechanisms of cold agglutinin disease, we investigated a human model of this syndrome in normal volunteers and in patients with diminished levels of serum complement. Subjects received intravenous injections of autologous, chromated (51Cr) erythrocytes which had been exposed in vitro to purified cold agglutinin preparations and to fresh autologous serum (as a source of complement). In vitro tests confirmed that such cells were coated with activated complement components (C3b), but not with immunoglobulin. Studies of erythrocyte clearance and simultaneous organ scanning showed that erythrocytes sensitized with low levels of cold agglutinin primarily undergo reticuloendothelial sequestration by the liver rather than intravascular hemolysis. After the initial sequestration of C3b-coated erythrocytes, a fraction of the cells are released back into the circulation and survive normally thereafter. Both phenomena are dose dependent and closely follow the sequestration and release pattern observed with IgM isoagglutinin sensitization. Experiments that used heated autologous serum as a source of B3 inactivator demonstrated that functionally intact C3b is required for hepatic sequestration. Erythrocytes coated with C3d were not cleared from the circulation. In vitro assays that sued human macrophage monolayers suggested that the intrahepatic conversion of C3b to C3d is responsible for the release of sensitized erythrocytes back into the circulation. The clearance of cold agglutinin-sensititzed erythrocytes was compared to the clearance mediated by IgM isoagglutinin. We found that the rate of complement fixation by an IgM antibody proceeds rapidly in vivo that the time for complement activation is not a factor in limiting the rate of hepatic sequestration. The major limiting factor appears to be the rate of liver blood flow. Maximal in vitro coating of erythrocytes with C3d conferred protection from further cold agglutinin sensitization but not from IgM isoagglutinin-mediated clearance. This suggests a mechanism for the resistance to lysis observed in cells obtained from patients with the cold agglutinin syndrome and confirms the marked dependence of the site of C3 attachment on the site of membrane localization of the sensitizing antibody.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 965497      PMCID: PMC333257          DOI: 10.1172/JCI108547

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Blood-group antibodies and red-cell destruction.

Authors:  P L MOLLISON
Journal:  Br Med J       Date:  1959-11-21

2.  The destruction of red cells by antibodies in man. I. Observations of the sequestration and lysis of red cells altered by immune mechanisms.

Authors:  J H JANDL; A R JONES; W B CASTLE
Journal:  J Clin Invest       Date:  1957-10       Impact factor: 14.808

3.  The disappearance rate of colloidal radio-gold from the circulation and its application to the estimation, of liver blood flow in normal and cirrhotic subjects.

Authors:  H VETTER; R FALKNER; A NEUMAYR
Journal:  J Clin Invest       Date:  1954-12       Impact factor: 14.808

4.  The measurement of liver circulation by means of the colloid disappearance rate. I. Liver blood flow in normal young men.

Authors:  E L DOBSON; G F WARNER; C R FINNEY; M E JOHNSTON
Journal:  Circulation       Date:  1953-05       Impact factor: 29.690

5.  Chronic hemolytic anemia due to cold agglutinins: the mechanism of resistance of red cells to C' hemolysis by cold agglutinins.

Authors:  R S Evans; E Turner; M Bingham
Journal:  J Clin Invest       Date:  1967-09       Impact factor: 14.808

Review 6.  Cold agglutination. Antibodies and antigens.

Authors:  D Roelcke
Journal:  Clin Immunol Immunopathol       Date:  1974-01

7.  Autoimmune haemolytic anaemias. V. studies on the resistance against complement haemolysis of the red cells of patients with chronic cold agglutinin disease.

Authors:  C P Engelfriet; A E Von dem Borne; D Beckers; E Reynierse; J J Van Loghem
Journal:  Clin Exp Immunol       Date:  1972-06       Impact factor: 4.330

8.  Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G.

Authors:  H Huber; M J Polley; W D Linscott; H H Fudenberg; H J Müller-Eberhard
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

Review 9.  Current problems of chronic cold hemagglutinin disease.

Authors:  H Schubothe
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

10.  The immune adherence receptor: dissociation between the expression of erythrocyte and mononuclear cell C3b receptors.

Authors:  I K Rothman; J A Gelfand; A S Fauci; M M Frank
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

View more
  28 in total

1.  Pathogenesis of hemolysis in immune hemolytic anemia.

Authors:  J R Cohen
Journal:  West J Med       Date:  1977-10

Review 2.  Cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Elevated natural killer (NK) cytotoxicity of mononuclear leucocytes from splenectomized patients: increase in Leu-7+ and Leu-11+ leucocytes.

Authors:  A Ferrante; G K Kiroff; P A Drew
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

Review 4.  Complement activation and complement receptors in systemic lupus erythematosus.

Authors:  J P Atkinson
Journal:  Springer Semin Immunopathol       Date:  1986

5.  A new look at reticuloendothelial blockade.

Authors:  J W Bradfield
Journal:  Br J Exp Pathol       Date:  1980-12

6.  Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.

Authors:  Ulrich Jäger; Shirley D'Sa; Christian Schörgenhofer; Johann Bartko; Ulla Derhaschnig; Christian Sillaber; Petra Jilma-Stohlawetz; Michael Fillitz; Thomas Schenk; Gary Patou; Sandip Panicker; Graham C Parry; James C Gilbert; Bernd Jilma
Journal:  Blood       Date:  2018-12-17       Impact factor: 22.113

7.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 8.  The role of complement in immune clearance of blood cells.

Authors:  U E Nydegger; M D Kazatchkine
Journal:  Springer Semin Immunopathol       Date:  1983

9.  Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease.

Authors:  C J Parker; C M Soldato; M J Telen
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.